Pharmaceutical company Strides Arcolab announced that it has bagged US health regulator's nod to sell the first liquid injection sterile product from its novel sterile injectable complex in the state of Karnataka.

But, Strides Arcolab stated that it was not in a position to reveal the name of the product because of privacy.

Agila Specialties CEO Venkat Iyer stated, "The USFDA approval for the product from the new site will go a long way in ameliorating product shortages in the critical therapeutic areas."

Agila Specialties is the company's completely owned specialities arm.

Mr. Iyer also said, "Two significant product approvals from the new facility augur well for the launch of a series of products in the USA during 2011."

Previously, Strides declared authorization for Vancomycin jab, an antibiotic utilized to take care of grave bacterial infections, from its novel plant in Bangalore.

The company has already begun the supplies to the United States market from the last month.

The stock of the company, on April 13, closed at Rs 386.20, up 0.6%, on the Bombay Stock Exchange (BSE).

Current EPS & P/E ratio stood at 31.59 and 12.23 respectively.

The share price has seen a 52-week high of Rs 477.7540 and a low of Rs 309.05 on BSE.